BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.: A Gross Profit Performance Breakdown

Biotech Giants' Profit Growth: BioMarin vs. MiMedx

__timestampBioMarin Pharmaceutical Inc.MiMedx Group, Inc.
Wednesday, January 1, 2014621276000105558000
Thursday, January 1, 2015737887000167094000
Friday, January 1, 2016907234000212608000
Sunday, January 1, 20171071860000285920000
Monday, January 1, 20181175948000322725000
Tuesday, January 1, 20191344582000256174000
Wednesday, January 1, 20201336183000208904000
Friday, January 1, 20211375760000215332000
Saturday, January 1, 20221612370000219525000
Sunday, January 1, 20231842161000266843000
Monday, January 1, 20242273680000
Loading chart...

Unleashing the power of data

A Tale of Two Biotech Giants: BioMarin vs. MiMedx

In the competitive world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, BioMarin Pharmaceutical Inc. and MiMedx Group, Inc. have showcased contrasting trajectories in their gross profit margins. From 2014 to 2023, BioMarin's gross profit surged by nearly 200%, peaking at approximately $1.84 billion in 2023. This growth reflects BioMarin's strategic advancements and robust product pipeline.

Conversely, MiMedx Group, Inc. experienced a more modest increase, with gross profits rising by about 150% over the same period, reaching around $267 million in 2023. Despite the slower growth, MiMedx's focus on regenerative medicine continues to hold promise. This financial snapshot underscores the dynamic nature of the biotech industry, where innovation and strategic positioning can lead to significant financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025